Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIsoDE: Psilocybin in Treatment-Resistant Depression
NCT04670081Phase 2Completed
- Sponsor
- Central Institute of Mental Health
- Start
- Jun 2021
- Primary completion
- Feb 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in treatment-resistant depression (TRD) (3 arms), sponsored by Central Institute of Mental Health. Primary endpoint: Treatment Response (HAM-D) at 6 weeks. Started Jun 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT04670081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04670081.